Welcome to our dedicated page for Panbela Therapeutics news (Ticker: PBLA), a resource for investors and traders seeking the latest updates and insights on Panbela Therapeutics stock.
Panbela Therapeutics Inc. (PBLA) is a clinical-stage biopharmaceutical company pioneering therapies targeting polyamine metabolism in aggressive cancers. This page serves as the definitive source for verified news and press releases related to clinical trials, research breakthroughs, and corporate developments.
Investors and researchers will find timely updates on PBLA's oncology pipeline, including ivospemin (SBP-101) and combination therapies under investigation. Our curated collection provides essential context for understanding the company's progress in pancreatic, ovarian, and other solid tumor research.
Key content categories include clinical trial milestones, regulatory updates, peer-reviewed data publications, and strategic partnership announcements. All materials are sourced directly from the company and reputable medical journals to ensure accuracy.
Bookmark this page for streamlined access to PBLA's latest developments in cancer therapeutics. For comprehensive analysis of how these updates may impact therapeutic landscapes and investment considerations, consult your financial advisor or medical professional.
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) has announced reaching 50% enrollment for its ASPIRE global clinical trial for the treatment of metastatic pancreatic cancer. The company expects full enrollment by Q1 2025 and anticipates interim data analysis on overall survival in mid-2024. The trial is a randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. With approximately 90 sites running globally, Panbela aims to deliver a more effective treatment for pancreatic cancer, a deadly disease with limited treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.96%
Tags
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) announces positive clinical data from a Phase 1 study of high dose DFMO treatment in combination with chemotherapy for neuroblastoma patients. The study showed that DFMO treatment was well tolerated, with a median time-to-progression of 19.8 months. The overall objective response rate was 9%, and the progression-free survival at 2 years was 29.5%. These results suggest that CPP-1X is a safe, oral treatment option that may improve response rates in heavily pretreated relapsed refractory neuroblastoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.39%
Tags
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) announced a 1-for-20 reverse stock split to increase the market price per share and regain compliance with Nasdaq listing requirements. The split will reduce outstanding shares to an estimated 480 thousand and will affect all stockholders uniformly. The company's transfer agent will provide instructions for the exchange of shares, and fractional shares will be paid in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.92%
Tags
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announces agreements with holders of existing warrants to exercise for 2,556,000 shares of common stock, raising approximately $2.0 million. The exercise of new warrants is subject to stockholder approval. The new warrants will be exercisable for up to 5,112,000 shares of common stock at an exercise price of $0.95 per share and will remain exercisable for up to five years after stockholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.58%
Tags
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announced that US WorldMeds received FDA approval for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients. The approval marks the first FDA approval of an NDA for any polyamine targeted therapy in a cancer indication. Panbela divested its pediatric neuroblastoma program to USWM in an arrangement entitling Panbela to up to approximately $9.5 million of non-dilutive funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
121.01%
Tags
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announces the publication of preclinical data from studies of ivospemin and eflornithine research in multiple myeloma. The results demonstrate the anti-neoplastic potential of ivospemin and CPP-1X, offering a compelling rationale for its clinical development as a promising treatment option for multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.36%
Tags
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) receives positive recommendation from the independent Data Safety Monitoring Board (DSMB) for the Phase 3 ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma. The DSMB has recommended that the study continue without modification after reviewing safety data for 214 treated patients. The ASPIRE Trial is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. No safety concerns were identified, and the company is looking forward to the interim analysis in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) provided a business update and reported financial results for Q3 2023. Recent highlights include collaborations, clinical trial updates, and financial/business developments, such as the divestiture of assets within the pediatric neuroblastoma program to US WorldMeds for an upfront payment of $400,000 and contingent payments totaling up to an additional $9.1 million. The company also announced new patents in China, Chile, and Australia, and a Phase 2 trial in castration resistant metastatic prostate cancer (mCRPC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
-
Rhea-AI Summary
Panbela Therapeutics, Inc. has entered into agreements with certain holders of its existing warrants to exercise their warrants at a reduced price of $0.78 per share. The exercise of the warrants is expected to generate approximately $1.9 million in gross proceeds. The new warrants will be exercisable into up to 4,260,000 shares of common stock at an exercise price of $0.78 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.21%
Tags
Rhea-AI Summary
Panbela Therapeutics announces the publication of preclinical and clinical data on DFMO treatment in recent onset type 1 diabetes. The data shows that DFMO treatment may preserve β cell function and improve patient outcomes. The Phase 1 clinical study demonstrated that CPP-1X was well tolerated and showed a dose-dependent inhibition of ODC. The study also found that treatment with CPP-1X stabilized C-peptide levels compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.2%
Tags
Panbela Therapeutics Inc